Abstract:Should cyclophosphamide be a first-line medication for class V lupus nephritis? Comment on the article by Hahn et al
To the Editor:We read with interest the guidelines for the screening, treatment, and management of lupus nephritis (LN) recently published in Arthritis Care & Research (1). This article provided insightful guidance on the management of LN. However, there are some comments we would like to make.Class V LN occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus. In the Recommend… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.